Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Zolbetuximab with nab-paclitaxel and gemcitabine for previously untreated metastatic CLDN18.2-positive pancreatic adenocarcinoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Zolbetuximab (IMAB362)	Pancreatic cancer	Gastrointestinal Cancer	2024	View \| Download
Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line	Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Tislelizumab (BGB-A317; BGBA-317)	Nasopharyngeal cancer	Head and Neck Cancer	2021	View \| Download
siG12D‐LODER in addition to standard chemotherapy for locally advanced pancreatic cancer	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , siG12D-LODER	Pancreatic cancer	Gastrointestinal Cancer	2018	View \| Download
Pembrolizumab in combination with gemcitabine and cisplatin for previously untreated advanced/unresectable biliary tract cancer	Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Pembrolizumab (Keytruda; MK-3475)	Biliary tract cancer	Gastrointestinal Cancer	2021	View \| Download
PEGPH20 in addition to Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Pegvorhyaluronidase alfa (PEGPH20)	Pancreatic cancer	Gastrointestinal Cancer	2018	View \| Download
Neoadjuvant nivolumab with gemcitabine and cisplatin followed by adjuvant nivolumab for previously-untreated muscle-invasive bladder cancer	Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Bladder cancer	Urological Cancer	2023	View \| Download
Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma - Adjuvant Therapy	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Pancreatic cancer	Gastrointestinal Cancer	2017	View \| Download
Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Glofitamab (RG-6026) , Oxaliplatin , Rituximab (MabThera; Rituxan; RG 105)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Eryaspase in addition to chemotherapy for treating advanced or metastatic pancreatic cancer – second-line	Eryaspase (Graspa; ERY001) , FOLFOX4 , Gemcitabine (Gemzar; gemcitabine hydrochloride)	Pancreatic cancer	Gastrointestinal Cancer	2020	View \| Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line	Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride)	Biliary tract cancer	Gastrointestinal Cancer	2021	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications